These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36933049)

  • 1. Renal enhanced CT images reveal the tandem mechanism between tumor cells and immunocytes based on bulk/single-cell RNA sequencing.
    Liang H; Wu K; Wu R; Huang K; Deng Z; Chen H
    Funct Integr Genomics; 2023 Mar; 23(2):88. PubMed ID: 36933049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PYCR1 regulates glutamine metabolism to construct an immunosuppressive microenvironment for the progression of clear cell renal cell carcinoma.
    Wei X; Zhang X; Wang S; Wang Y; Ji C; Yao L; Song N
    Am J Cancer Res; 2022; 12(8):3780-3798. PubMed ID: 36119844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptome mapping of renal clear cell carcinoma revealed by machine learning algorithm based on enhanced computed tomography images.
    Yang Y; Huang H; Liang H
    J Gene Med; 2023 Jul; 25(7):e3494. PubMed ID: 36869574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
    Chen Y; He J; Jin T; Zhang Y; Ou Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
    Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
    Front Immunol; 2021; 12():734646. PubMed ID: 34795663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deciphering glutamine metabolism patterns for malignancy and tumor microenvironment in clear cell renal cell carcinoma.
    Wu G; Li T; Chen Y; Ye S; Zhou S; Tian X; Anwaier A; Zhu S; Xu W; Hao X; Ye D; Zhang H
    Clin Exp Med; 2024 Jul; 24(1):152. PubMed ID: 38970690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a Seven-Gene Signature Associated with CD8
    Chen Y; Zhou X; Xie Y; Wu J; Li T; Yu T; Pang Y; Du W
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of an interferon regulatory factors-related risk model for predicting prognosis, immune microenvironment and immunotherapy in clear cell renal cell carcinoma.
    Pan H; Lu W; Zhang M; Liu C
    Front Oncol; 2023; 13():1131191. PubMed ID: 37182129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
    Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
    Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma.
    Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T
    Front Immunol; 2023; 14():1230267. PubMed ID: 37600792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated analysis of single-cell and bulk transcriptome identifies a signature based on NK cell marker genes to predict prognosis and therapeutic response in clear cell renal cell carcinoma.
    Wang K; Yu M; Zhang Z; Yin R; Chen Q; Zhao X; Yu H
    Transl Cancer Res; 2023 May; 12(5):1270-1289. PubMed ID: 37304554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Treg-related prognostic molecular subtypes and individualized characteristics in clear cell renal cell carcinoma through single-cell transcriptomes and bulk RNA sequencing.
    Weng KQ; Liu JY; Li H; She LL; Qiu JL; Qi H; Qi HY; Li YS; Dai YB
    Int Immunopharmacol; 2024 Mar; 130():111746. PubMed ID: 38442575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
    Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
    Front Immunol; 2022; 13():934243. PubMed ID: 36189255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma.
    Xing Q; Zeng T; Liu S; Cheng H; Ma L; Wang Y
    BMC Cancer; 2021 Apr; 21(1):381. PubMed ID: 33836688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of the metabolic reprogramming-associated gene signature for clear cell renal cell carcinoma prognosis prediction.
    Tai R; Leng J; Li W; Wu Y; Yang J
    BMC Urol; 2023 Sep; 23(1):147. PubMed ID: 37715154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
    Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
    Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma.
    Gui Z; Du J; Wu N; Shen N; Yang Z; Yang H; Wang X; Zhao N; Zeng Z; Wei R; Ma W; Wang C
    BMC Cancer; 2023 Jul; 23(1):649. PubMed ID: 37438709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell transcriptome analysis revealing the intratumoral heterogeneity of ccRCC and validation of MT2A in pathogenesis.
    Wang J; Zuo Z; Yu Z; Chen Z; Meng X; Ma Z; Niu J; Guo R; Tran LJ; Zhang J; Jiang T; Ye F; Ma B; Sun Z
    Funct Integr Genomics; 2023 Sep; 23(4):300. PubMed ID: 37713131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
    Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
    Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.